Pharma Focus Asia

Ipsen Developed First-of-its-kind for Metastatic Pancreatic Adenocarcinoma

Ipsen has developed a groundbreaking treatment called Onivyde® (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) for adults with metastatic pancreatic adenocarcinoma (mPDAC) as a first-line therapy.

The Phase III NAPOLI 3 trial results mark a significant advancement in the treatment of mPDAC, showing positive outcomes compared to the currently approved nab-paclitaxel and gemcitabine regimen.

This approval establishes the Onivyde (NALIRIFOX) regimen as a potential new standard-of-care option, offering proven survival benefits for individuals with mPDAC in the U.S.

Onivyde works by inhibiting an enzyme called topoisomerase I, crucial for DNA replication in cancer cells. Encapsulated in liposomes, irinotecan in Onivyde accumulates in tumours and releases gradually over time. 

The treatment is administered via intravenous infusion every two weeks, with dosage adjustments as needed. Onivyde can now be prescribed immediately in the U.S. for eligible treatment-naïvoe individuals or those who have undergone gemcitabine-based therapy.

PDAC is the most prevalent type of pancreatic cancer, with a significant number of diagnoses annually in the U.S. and globally. Often detected late due to nonspecific symptoms, PDAC typically progresses rapidly to metastatic stages, resulting in poor prognoses and low survival rates.

Metastatic pancreatic adenocarcinoma poses considerable challenges in treatment, with limited options available. 

Onivyde stands out as the only FDA-approved regimen demonstrating efficacy in multiple phase III trials across different lines of therapy for mPDAC.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024